Nogo-A has been an obstacle for thirty years. This protein resides in the sheaths of nerve fibers throughout the spinal cord and brain, apparently doing nothing beneficial, yet effectively preventing damaged nerves from healing. After an injury, when the body urgently requires axons to regenerate and reconnect, Nogo-A remains present, hindering the process like a bouncer oblivious that the event has ended. Researchers at the University of Zurich have now demonstrated, for the first time using live imaging, precisely how an antibody named NG101 alleviates that obstacle and what occurs in the spinal cord as a result.<\/p>\n
These findings are significant because we have not been able to observe the impact of a regenerative treatment in a human spinal cord and actually witness the tissue’s response until now. This alters many aspects.<\/p>\n
Spinal cord injuries are exceptionally harsh in a specific manner. The damage may be momentary\u2014an accident, a fall, a misjudged dive\u2014but the repercussions spread over months and years. The spinal cord continues to deteriorate. Axons that were intact during the injury begin to degenerate. Myelin diminishes. The nervous system, which cannot regenerate like skin or bone, withdraws instead of reconstructing. What the Zurich team has been diligently pursuing is a method to halt this withdrawal. NG101 was identified at the university roughly thirty years ago. It specifically targets Nogo-A, neutralizing it so that nerve fibers are not obstructed from forming new connections. Clinical trials for patients with acute cervical injuries started in 2019 under the multinational NISCI program. Results released in late 2024 indicated that the antibody was safe and seemed to enhance upper extremity motor function. However, the mechanism had not been determined: not in humans, not in living tissue, not in real-time.<\/p>\n
Observing the Spinal Cord Regenerate<\/p>\n
This is what the new Nature Communications study reveals. Utilizing high-resolution MRI on 106 participants over six months, Patrick Freund\u2019s team at Balgrist University Hospital monitored two simultaneous processes. First, the lesion itself. Second, the cord both above and below it.<\/p>\n
The lesion outcomes were remarkable on their own. In patients receiving NG101, the volume of damaged tissue decreased by approximately 52 cubic millimeters per month. In the placebo group, it dwindled by nearly 2. More revealing was the focus of the reduction: mainly within the corticospinal tracts, the descending pathways that convey motor signals from the brain to the muscles. The dorsal columns, which transmit sensory signals upward, demonstrated similar rates of change in both groups. That tract-specific pattern eliminates the obvious alternative hypothesis that the treated patients were simply resolving edema faster. Comprehensive fluid resolution would impact everything uniformly. This did not occur.<\/p>\n
The remote outcomes were perhaps even more astonishing. Even centimeters above the injury site, at the C1-C2 level of the cervical cord, the spinal cord in untreated patients was noticeably atrophying, losing roughly 0.6 square millimeters of cross-sectional area monthly. Standard Wallerian degeneration, the gradual dying off of axons disconnected from their targets, proceeded as anticipated. In the NG101 group, that same measure remained essentially unchanged. Myelin content, monitored using a technique known as magnetization transfer saturation, exhibited a corresponding pattern: steady loss in controls, relative stability in treated individuals. \u201cWe are now able to objectively visualize the effect of the therapy early on,\u201d Freund stated. \u201cThis allows for more strategic use of future treatments and conducting a more reliable evaluation of their outcomes.\u201d<\/p>\n
The imaging likely captures a combination of factors, according to the researchers. Some regenerative sprouting around the lesion, as new axons find routes around the damaged area. Some shielding of intact fibers that would have otherwise degenerated. The antibody, in Freund\u2019s description, accomplishes both: slowing the retreat while promoting a slight advance. \u201cThis facilitates surviving and newly regenerated nerve fibers to re-establish connections with the spinal cord centers that govern the hand, arm, and leg nerves,\u201d he remarked. \u201cThese connections are crucial for transmitting signals from the brain to the muscles.\u201d<\/p>\n
The Signal Concealed in the Noise<\/p>\n
One finding contradicts the trend in an enlightening way. Among patients classified as motor-complete (indicating the injury severed all voluntary motor function below the damage level), NG101 caused structural changes similar to those observed in less severe cases: slower cord atrophy, improved myelin preservation. However, these patients showed no corresponding enhancement in arm or hand function. None whatsoever. This might seem like a shortcoming, but the researchers interpret it differently. The structural protection occurs even when the functional benefit isn\u2019t yet measurable. This implies that behavioral outcomes, the scores and tests we utilize to gauge recovery, are a rather imprecise tool for detecting the actual happenings within the cord. <\/p>\n
That realization directly influences one<\/p>\n","protected":false},"excerpt":{"rendered":"
Nogo-A has been an obstacle for thirty years. This protein resides in the sheaths of nerve fibers throughout the spinal cord and brain, apparently doing nothing beneficial, yet effectively preventing damaged nerves from healing. After an injury, when the body urgently requires axons to regenerate and reconnect, Nogo-A remains present, hindering the process like a […]<\/p>\n","protected":false},"author":1,"featured_media":372312,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[179],"class_list":["post-372311","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-source-scienceblog-com"],"_links":{"self":[{"href":"https:\/\/wolfscientific.com\/index.php?rest_route=\/wp\/v2\/posts\/372311","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wolfscientific.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wolfscientific.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wolfscientific.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/wolfscientific.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=372311"}],"version-history":[{"count":0,"href":"https:\/\/wolfscientific.com\/index.php?rest_route=\/wp\/v2\/posts\/372311\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wolfscientific.com\/index.php?rest_route=\/wp\/v2\/media\/372312"}],"wp:attachment":[{"href":"https:\/\/wolfscientific.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=372311"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wolfscientific.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=372311"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wolfscientific.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=372311"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}